Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing a biotech filing packed with plasma kallikrein science can feel overwhelming. KalVista Pharmaceuticals’ 10-K routinely spans hundreds of pages covering cash burn, trial endpoints, and risk factors unique to rare-disease drug development. Finding when executives file Form 4 insider trades—or whether an 8-K flags a clinical setback—takes time most professionals don’t have.
Our platform solves this. Stock Titan’s AI reads every KalVista Pharmaceuticals annual report 10-K simplified and each KalVista Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR. It then serves plain-English summaries that answer the questions investors actually search for, like “understanding KalVista Pharmaceuticals SEC documents with AI” or “KalVista Pharmaceuticals earnings report filing analysis”. Need real-time alerts? We surface KalVista Pharmaceuticals Form 4 insider transactions real-time, highlight option exercises, and cross-link to KalVista Pharmaceuticals insider trading Form 4 transactions history so you can monitor sentiment before key readouts.
Beyond headline numbers, our reports map trial spending to pipeline stage, flag shelf-registration gestures that hint at future raises, and decode the jargon inside every KalVista Pharmaceuticals proxy statement executive compensation. You’ll also see concise breakdowns of material events—“KalVista Pharmaceuticals 8-K material events explained”—and alerts on KalVista Pharmaceuticals executive stock transactions Form 4. Whether you’re modeling cash runway or tracking the new Factor XIIa program, Stock Titan delivers the data, context, and AI-powered clarity you need—without wading through endless pages.
KalVista Pharmaceuticals insider grant: An officer, Chief Operations Officer Arif Bilal, was granted 100,000 stock options exercisable at
Arif Bilal, listed as Chief Operations Officer and a director of KalVista Pharmaceuticals, Inc. (KALV), filed an initial Form 3 reporting that no securities are beneficially owned as of the event date
KalVista Pharmaceuticals (KALV) disclosed an employment agreement for a newly named executive, Mr. Arif, detailing compensation and termination protections. The agreement sets a
If terminated by the company without cause or by Mr. Arif for good reason, he is entitled to a lump-sum payment equal to 12 months of base salary and 12 months of COBRA reimbursement. Within
The filing includes a Form of Indemnification Agreement reference and notes a press release dated
KalVista Pharmaceuticals, Inc. director Brian JG Pereira was granted a stock option on 10/01/2025 to buy 30,000 shares of common stock at a conversion price of $12.05. The option was reported on Form 4 filed on 10/02/2025 and is exercisable in installments over a 12-month vesting schedule beginning 11/01/2025, with 1/12th of the total shares vesting initially and then monthly thereafter, subject to continued service. The option expires on 09/30/2035. Following the grant, Mr. Pereira directly beneficially owns 30,000 option shares.
Stuart Nancy, a director of KalVista Pharmaceuticals, Inc. (KALV), was granted a stock option on 10/01/2025 to buy 30,000 shares of common stock at an exercise price of $12.05 per share. The option vests over a 12‑month period, with the first 1/12th vesting on November 1, 2025 and then monthly thereafter, subject to continued service. The option expires on 09/30/2035. After the reported transaction, the filing shows 30,000 shares beneficially owned following the grant, held directly. The Form 4 was signed by an attorney‑in‑fact, Benjamin L. Palleiko, on 10/02/2025.
KalVista Pharmaceuticals, Inc. (KALV) director William Fairey reported the vesting of a stock option award. On 10/01/2025 a grant coded as a vesting event (Code V) covered 30,000 stock options with an exercise price of $12.05. Following the reported transaction, the filing shows 30,000 shares beneficially owned directly. The option vests over a 12‑month period, beginning with 1/12th vesting on November 1, 2025 and then monthly thereafter, subject to continued service. The filing is signed by attorney‑in‑fact Benjamin L. Palleiko on 10/02/2025.
Edward W. Unkart, a director of KalVista Pharmaceuticals, Inc. (KALV), reported an acquisition of a stock option on 10/01/2025. The option grants the right to buy 30,000 shares of common stock at an exercise price of $12.05. The option vests over a 12‑month period beginning with a first vesting of 1/12th on November 1, 2025, then monthly thereafter, subject to continued service. The option becomes exercisable and expires on 09/30/2035, and the reporting person is shown as holding 30,000 shares beneficially following the transaction. The Form 4 was signed on behalf of the reporting person on 10/02/2025.
KalVista Pharmaceuticals, Inc. disclosed the appointment of Ms. Sensenig as a non-employee director and the associated compensation arrangements. Her initial board award consists of options to purchase 45,000 shares of the company's common stock. She will receive an annual cash retainer of $42,500 plus an additional $10,000 per year for service on the Audit Committee. The disclosure is a routine corporate governance item describing director pay terms.
KalVista Pharmaceuticals, Inc. filed an 8-K reporting the execution of an indenture for a new convertible debt instrument and related press releases. The filing references an indenture dated
KalVista Pharmaceuticals, Inc. (KALV) reported mixed operational and clinical disclosures in this 10-Q excerpt. The company had a 100.0 million share registration ("ATM Shares") available under an S-3 prospectus supplement but did not offer or sell any ATM Shares during the three months ended July 31, 2025. Trade accounts receivable arise from product sales to specialty distributors and pharmacies; as of April 30, 2025 the company reported $0 of accounts receivable, net related to product sales and no reserve for credit losses. The filing describes fair value sensitivity for a derivative liability and discloses a $132.3 million royalty obligation as of July 31, 2025, with an embedded derivative carrying a fair value of $9.4 million. A licensing arrangement (Kaken Agreement) included an $11.0 million non-refundable upfront payment, potential regulatory and sales milestones of approximately $13.0 million, and effective royalties in the mid-twenties percent on Japanese pricing, for a 10-year initial term. The company also details commercial terms tied to annual net sales thresholds and a $50.0 million sales-based milestone if sebetralstat achieves at least $550.0 million in annual net sales before 2031. Clinically, EKTERLY (sebetralstat) is described as an oral, on-demand HAE therapy; 600 mg dosing showed statistically significant faster reduction in attack severity (p=0.0032) and faster complete attack resolution (p<0.0001) versus placebo.
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
